Aktienanalyse zu Elicio Therapeutics Inc (ELTX)ELTXElicio Therapeutics Inc

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Elicio Therapeutics Inc is not a good buy right now due to its current price of $1.59, a significantly low RSI of 34.022 indicating oversold conditions, and a staggering year-to-date change of -80.25%. The company is facing financial challenges, highlighted by a net income loss of $14 million in Q4 2024 and a projected EPS of -0.42 for the upcoming earnings report. The main risk is the ongoing clinical trial setbacks, which have led to a bearish sentiment among investors, as reflected in the stock's decline of over 36% this year.